Nanotherapeutic Strategies for the Treatment of Alzheimer's Disease

References

• Addressing global dementia (Editorial) . Lancet383 (9936), 2185 (2014).
   PubMed Web of Science ®Google Scholar
• Hardy J Selkoe DJ . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science297 (5580), 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Mondragon-Rodriguez S Perry G Zhu X et al. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer's disease. Oxid. Med. Cell. Longev.940603 (2013).
   PubMed Web of Science ®Google Scholar
• Manafirad A Farzadfar F Habibi L et al. Is Amyloid-β an innocent bystander and marker in Alzheimer's disease? Is the liability of multivalent cation homeostasis and its influence on amyloid-β function the real mechanism? J. Alzheimers Dis. 42 (1), 69–85 (2014).
   PubMed Web of Science ®Google Scholar
• Huang Y Mucke L . Alzheimer mechanisms and therapeutic strategies. Cell148 (6), 1204–1222 (2012).
   PubMed Web of Science ®Google Scholar
• Spuch C Saida O Navarro C . Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat. Drug Deliv. Formul.6 (1), 2–18 (2012).
   PubMedGoogle Scholar
• Foley P . Lipids in Alzheimer's disease: A century-old story. Biochim. Biophys. Acta1801 (8), 750–753 (2010).
   PubMed Web of Science ®Google Scholar
• Haass C Kaether C Thinakaran G et al. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med.2 (5), a6270 (2012).
   Google Scholar
• Wang Y Xia Z Xu JR et al. Alpha-mangostin, a polyphenolic xanthone derivative from mangosteen, attenuates β-amyloid oligomers-induced neurotoxicity by inhibiting amyloid aggregation. Neuropharmacology62 (2), 871–881 (2012).
   PubMed Web of Science ®Google Scholar
• Gilbert BJ . The role of amyloid-β in the pathogenesis of Alzheimer's disease. J. Clin. Pathol.66 (5), 362–366 (2013).
   PubMed Web of Science ®Google Scholar
• Blennow K de Leon MJ Zetterberg H . Alzheimer's disease. Lancet368 (9533), 387–403 (2006).
   PubMed Web of Science ®Google Scholar
• Spillantini MG Goedert M . Tau pathology and neurodegeneration. Lancet Neurol.12 (6), 609–622 (2013).
   PubMed Web of Science ®Google Scholar
• Bartus RT . On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol.163 (2), 495–529 (2000).
   PubMed Web of Science ®Google Scholar
• Camps P Munoz-Torrero D . Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev. Med. Chem.2 (1), 11–25 (2002).
   PubMed Web of Science ®Google Scholar
• Padurariu M Ciobica A Lefter R et al. The oxidative stress hypothesis in Alzheimer's disease. Psychiatr. Danub.25 (4), 401–409 (2013).
   PubMed Web of Science ®Google Scholar
• Massaad CA . Neuronal and vascular oxidative stress in Alzheimer's disease. Curr. Neuropharmacol.9 (4), 662–673 (2011).
   PubMed Web of Science ®Google Scholar
• Tiiman A Palumaa P Tougu V . The missing link in the amyloid cascade of Alzheimer's disease–metal ions. Neurochem. Int.62 (4), 367–378 (2013).
   PubMed Web of Science ®Google Scholar
• Barcia E Salama A Fernandez-Carballido A et al. Protective effects of clioquinol on human neuronal-like cells: a new formulation of clioquinol-loaded PLGA microspheres for Alzheimer's disease. J. Drug Target19 (8), 637–646 (2011).
   PubMed Web of Science ®Google Scholar
• de Boer AG Gaillard PJ . Strategies to improve drug delivery across the blood–brain barrier. Clin. Pharmacokinet.46 (7), 553–576 (2007).
   PubMed Web of Science ®Google Scholar
• Ronaldson PT Davis TP . Blood–brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr. Pharm. Des.18 (25), 3624–3644 (2012).
   PubMed Web of Science ®Google Scholar
• Reese TS Karnovsky MJ . Fine structural localization of a blood–brain barrier to exogenous peroxidase. J. Cell Biol.34 (1), 207–217 (1967).
   PubMed Web of Science ®Google Scholar
• Lai CH Kuo KH . The critical component to establish in vitro BBB model: pericyte. Brain Res. Brain Res. Rev.50 (2), 258–265 (2005).
   PubMedGoogle Scholar
• Abbott NJ Ronnback L Hansson E . Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci.7 (1), 41–53 (2006).
   PubMed Web of Science ®Google Scholar
• Mahringer A Ott M Reimold I et al. The ABC of the blood–brain barrier-regulation of drug efflux pumps. Curr. Pharm. Des.17 (26), 2762–2770 (2011).
   PubMed Web of Science ®Google Scholar
• Bendayan R Ronaldson PT Gingras D et al. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J. Histochem. Cytochem.54 (10), 1159–1167 (2006).
   PubMed Web of Science ®Google Scholar
• Sanchez-Covarrubias L Slosky LM Thompson BJ et al. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr. Pharm. Des. 20 (10), 1422–1449 (2014).
   PubMed Web of Science ®Google Scholar
• Wong HL Wu XY Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev.64 (7), 686–700 (2012).
   PubMed Web of Science ®Google Scholar
• Ronaldson PT Finch JD Demarco KM et al. Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood–brain barrier. J. Pharmacol. Exp. Ther.336 (3), 827–839 (2011).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . Drug targeting to the brain. Pharm. Res.24 (9), 1733–1744 (2007).
   PubMed Web of Science ®Google Scholar
• Alafuzoff I Adolfsson R Bucht G et al. Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia. J. Neurol. Sci.60 (3), 465–472 (1983).
   PubMed Web of Science ®Google Scholar
• Banks WA Kumar VB Farr SA et al. Impairments in brain-to-blood transport of amyloid-β and reabsorption of cerebrospinal fluid in an animal model of Alzheimer's disease are reversed by antisense directed against amyloid-β protein precursor. J. Alzheimers Dis.23 (4), 599–605 (2011).
   PubMed Web of Science ®Google Scholar
• Erickson MA Banks WA . Blood–brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J. Cereb. Blood Flow Metab.33 (10), 1500–1513 (2013).
   PubMed Web of Science ®Google Scholar
• Lacalle-Aurioles M Mateos-Perez JM Guzman-De-Villoria JA et al. Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer's disease. J. Cereb. Blood Flow Metab.34 (4), 654–659 (2014).
   PubMed Web of Science ®Google Scholar
• Miyakawa T Shimoji A Kuramoto R et al. The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. Virchows Arch. B, Cell Pathol.40 (2), 121–129 (1982).
   Google Scholar
• Jancso G Domoki F Santha P et al. β-amyloid (1–42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci. Lett.253 (2), 139–141 (1998).
   PubMed Web of Science ®Google Scholar
• Kook SY Hong HS Moon M et al. Aβ1–42-RAGE interaction disrupts tight junctions of the blood–brain barrier via Ca2+-calcineurin signaling. J. Neurosci.32 (26), 8845–8854 (2012).
   PubMed Web of Science ®Google Scholar
• Do TM Alata W Dodacki A et al. Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimer's disease. Neuropharmacology81, 311–317 (2014).
   PubMed Web of Science ®Google Scholar
• Burgmans S van de Haar HJ Verhey FR et al. Amyloid-β interacts with blood–brain barrier function in dementia: a systematic review. J. Alzheimers Dis.35 (4), 859–873 (2013).
   PubMed Web of Science ®Google Scholar
• Hartz AM Bauer B Soldner EL et al. Amyloid-β contributes to blood–brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke43 (2), 514–523 (2012).
   PubMed Web of Science ®Google Scholar
• Donahue JE Flaherty SL Johanson CE et al. RAGE, LRP-1, and amyloid-β protein in Alzheimer's disease. Acta Neuropathol.112 (4), 405–415 (2006).
   PubMed Web of Science ®Google Scholar
• Deane R Du Yan S Submamaryan RK et al. RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brain. Nat. Med.9 (7), 907–913 (2003).
   PubMed Web of Science ®Google Scholar
• Deane R Zlokovic BV . Role of the blood–brain barrier in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res.4 (2), 191–197 (2007).
   PubMed Web of Science ®Google Scholar
• Hartz AM Miller DS Bauer B . Restoring blood–brain barrier P-glycoprotein reduces brain amyloid-β in a mouse model of Alzheimer's disease. Mol. Pharmacol.77 (5), 715–723 (2010).
   PubMed Web of Science ®Google Scholar
• Miller DS Bauer B Hartz AM . Modulation of P-glycoprotein at the blood–brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol. Rev.60 (2), 196–209 (2008).
   PubMed Web of Science ®Google Scholar
• Cirrito JR Deane R Fagan AM et al. P-glycoprotein deficiency at the blood–brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J. Clin. Invest.115 (11), 3285–3290 (2005).
   PubMed Web of Science ®Google Scholar
• Bauer B Hartz AM Miller DS . Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood–brain barrier. Mol. Pharmacol.71 (3), 667–675 (2007).
   PubMed Web of Science ®Google Scholar
• McDade E Kim A James J et al. Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology83 (8), 710–717 (2014).
   PubMed Web of Science ®Google Scholar
• Banks WA . Drug delivery to the brain in Alzheimer's disease: consideration of the blood–brain barrier. Adv. Drug Deliv. Rev.64 (7), 629–639 (2012).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . The blood–brain barrier and neurotherapeutics. NeuroRx2 (1), 1–2 (2005).
   PubMedGoogle Scholar
• Gabathuler R . Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiol. Dis.37 (1), 48–57 (2010).
   PubMed Web of Science ®Google Scholar
• Fung LK Shin M Tyler B et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res.13 (5), 671–682 (1996).
   PubMed Web of Science ®Google Scholar
• Barua NU Gill SS Love S . Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathol.24 (2), 117–127 (2013).
   PubMed Web of Science ®Google Scholar
• Barua NU Miners JS Bienemann AS et al. Convection-enhanced delivery of neprilysin: a novel amyloid-β-degrading therapeutic strategy. J. Alzheimers Dis.32 (1), 43–56 (2012).
   PubMed Web of Science ®Google Scholar
• Peng KA Masliah E . Lentivirus-expressed siRNA vectors against Alzheimer disease. Methods Mol. Biol.614, 215–224 (2010).
   PubMedGoogle Scholar
• Wahlberg LU Lind G Almqvist PM et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J. Neurosurg.117 (2), 340–347 (2012).
   PubMed Web of Science ®Google Scholar
• Perlstein B Ram Z Daniels D et al. Convection-enhanced delivery of maghemite nanoparticles: increased efficacy and MRI monitoring. Neuro. Oncol.10 (2), 153–161 (2008).
   PubMed Web of Science ®Google Scholar
• MacKay JA Deen DF Szoka FJ . Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res.1035 (2), 139–153 (2005).
   PubMed Web of Science ®Google Scholar
• Fortin D Gendron C Boudrias M et al. Enhanced chemotherapy delivery by intraarterial infusion and blood–brain barrier disruption in the treatment of cerebral metastasis. Cancer109 (4), 751–760 (2007).
   PubMed Web of Science ®Google Scholar
• Hynynen K McDannold N Vykhodtseva N et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J. Neurosurg.105 (3), 445–454 (2006).
   PubMed Web of Science ®Google Scholar
• Yao L Song Q Bai W et al. Facilitated brain delivery of poly (ethylene glycol)-poly (lactic acid) nanoparticles by microbubble-enhanced unfocused ultrasound. Biomaterials35 (10), 3384–3395 (2014).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . Blood–brain barrier drug targeting: the future of brain drug development. Mol. Interv.3 (2), 90–105 (2003).
   PubMedGoogle Scholar
• Patel MM Goyal BR Bhadada SV et al. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs.23 (1), 35–58 (2009).
   PubMed Web of Science ®Google Scholar
• Mittapalli RK Manda VK Adkins CE et al. Exploiting nutrient transporters at the blood–brain barrier to improve brain distribution of small molecules. Ther. Deliv.1 (6), 775–784 (2010).
   PubMedGoogle Scholar
• Cornford EM Young D Paxton JW et al. Melphalan penetration of the blood–brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res.52 (1), 138–143 (1992).
   PubMed Web of Science ®Google Scholar
• Mena I Cotzias GC . Protein intake and treatment of Parkinson's disease with levodopa. N. Engl. J. Med.292 (4), 181–184 (1975).
   PubMed Web of Science ®Google Scholar
• Uchino H Kanai Y Kim DK et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharmacol.61 (4), 729–737 (2002).
   PubMed Web of Science ®Google Scholar
• Schroeder U Sommerfeld P Ulrich S et al. Nanoparticle technology for delivery of drugs across the blood–brain barrier. J. Pharm. Sci.87 (11), 1305–1307 (1998).
   PubMed Web of Science ®Google Scholar
• Herve F Ghinea N Scherrmann JM . CNS delivery via adsorptive transcytosis. AAPS J.10 (3), 455–472 (2008).
   PubMed Web of Science ®Google Scholar
• Lu W . Adsorptive-mediated brain delivery systems. Curr. Pharm. Biotechnol.13 (12), 2340–2348 (2012).
   PubMed Web of Science ®Google Scholar
• Lockman PR Koziara JM Mumper RJ et al. Nanoparticle surface charges alter blood–brain barrier integrity and permeability. J. Drug Target12 (9–10), 635–641 (2004).
   PubMed Web of Science ®Google Scholar
• Dhuria SV Hanson LR Frey WN . Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci.99 (4), 1654–1673 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Y Zhao Y Dai CL et al. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp. Neurol.261C, 610–619 (2014).
   Google Scholar
• Yarchoan M Arnold SE . Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes63 (7), 2253–2261 (2014).
   PubMed Web of Science ®Google Scholar
• Aguzzi A O'Connor T . Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov.9 (3), 237–248 (2010).
   PubMed Web of Science ®Google Scholar
• Wong GT Manfra D Poulet FM et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem.279 (13), 12876–12882 (2004).
   PubMed Web of Science ®Google Scholar
• Luo Y Bolon B Kahn S et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci.4 (3), 231–232 (2001).
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti L Seow Y Yin H et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol.29 (4), 341–345 (2011).
   PubMed Web of Science ®Google Scholar
• Heffern MC Velasco PT Matosziuk LM et al. Modulation of amyloid-β aggregation by histidine-coordinating cobalt(III) schiff base complexes. Chembiochem.15 (11), 1584–1589 (2014).
   PubMed Web of Science ®Google Scholar
• Churches QI Caine J Cavanagh K et al. Naturally occurring polyphenolic inhibitors of amyloid-β aggregation. Bioorg. Med. Chem. Lett.24 (14), 3108–3112 (2014).
   PubMed Web of Science ®Google Scholar
• Takahashi T Mihara H . Peptide and protein mimetics inhibiting amyloid β-peptide aggregation. Acc. Chem. Res.41 (10), 1309–1318 (2008).
   PubMed Web of Science ®Google Scholar
• Pan H Soman NR Schlesinger PH et al. Cytolytic peptide nanoparticles (‘NanoBees’) for cancer therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.3 (3), 318–327 (2011).
   PubMed Web of Science ®Google Scholar
• Liu L Xu K Wang H et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol.4 (7), 457–463 (2009).
   PubMed Web of Science ®Google Scholar
• Li M Xu C Wu L et al. Self-assembled peptide-polyoxometalate hybrid nanospheres: two in one enhances targeted inhibition of amyloid β-peptide aggregation associated with Alzheimer's disease. Small9 (20), 3455–3461 (2013).
   PubMed Web of Science ®Google Scholar
• Shen Y Yu LC . Potential protection of curcumin against hypoxia-induced decreases in β-III tubulin content in rat prefrontal cortical neurons. Neurochem. Res.33 (10), 2112–2117 (2008).
   PubMed Web of Science ®Google Scholar
• Reinke AA Gestwicki JE . Structure-activity relationships of amyloid β-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem. Biol. Drug Des.70 (3), 206–215 (2007).
   PubMed Web of Science ®Google Scholar
• Lim GP Chu T Yang F et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci.21 (21), 8370–8377 (2001).
   PubMed Web of Science ®Google Scholar
• Sharma RA Gescher AJ Steward WP . Curcumin: the story so far. Eur. J. Cancer41 (13), 1955–1968 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng KK Yeung CF Ho SW et al. Highly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J.15 (2), 324–336 (2013).
   PubMed Web of Science ®Google Scholar
• Mathew A Fukuda T Nagaoka Y et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS ONE7 (3), e32616 (2012).
   PubMed Web of Science ®Google Scholar
• Kogan MJ Bastus NG Amigo R et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano. Lett.6 (1), 110–115 (2006).
   PubMed Web of Science ®Google Scholar
• Prades R Guerrero S Araya E et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials33 (29), 7194–7205 (2012).
   PubMed Web of Science ®Google Scholar
• Lee JH Engler JA Collawn JF et al. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. J. Biochem.268 (7), 2004–2012 (2001).
   PubMedGoogle Scholar
• Mawuenyega KG Sigurdson W Ovod V et al. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science330 (6012), 1774 (2010).
   PubMed Web of Science ®Google Scholar
• Cramer PE Cirrito JR Wesson DW et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science335 (6075), 1503–1506 (2012).
   PubMed Web of Science ®Google Scholar
• Prada CM Garcia-Alloza M Betensky RA et al. Antibody-mediated clearance of amyloid-β peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J. Neurosci.27 (8), 1973–1980 (2007).
   PubMed Web of Science ®Google Scholar
• Sagare A Deane R Bell RD et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med.13 (9), 1029–1031 (2007).
   PubMed Web of Science ®Google Scholar
• Song Q Huang M Yao L et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-β. ACS Nano8 (3), 2345–2359 (2014).
   PubMed Web of Science ®Google Scholar
• Lee CY Tse W Smith JD et al. Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem.287 (3), 2032–2044 (2012).
   PubMed Web of Science ®Google Scholar
• Canovi M Markoutsa E Lazar AN et al. The binding affinity of anti-Aβ1–42 MAb-decorated nanoliposomes to Aβ1–42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials32 (23), 5489–5497 (2011).
   PubMed Web of Science ®Google Scholar
• Wilcock DM Rojiani A Rosenthal A et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci.24 (27), 6144–6151 (2004).
   PubMed Web of Science ®Google Scholar
• DeMattos RB Bales KR Cummins DJ et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA98 (15), 8850–8855 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang C Wan X Zheng X et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials35 (1), 456–465 (2014).
   PubMed Web of Science ®Google Scholar
• Bartnik D Funke SA Andrei-Selmer LC et al. Differently selected D-enantiomeric peptides act on different Aβ species. Rejuvenation Res.13 (2–3), 202–205 (2010).
   PubMed Web of Science ®Google Scholar
• Li J Feng L Fan L et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials32 (21), 4943–4950 (2011).
   PubMed Web of Science ®Google Scholar
• Dong J Atwood CS Anderson VE et al. Metal binding and oxidation of amyloid-β within isolated senile plaque cores: Raman microscopic evidence. Biochemistry42 (10), 2768–2773 (2003).
   PubMed Web of Science ®Google Scholar
• Ehmann WD Markesbery WR Alauddin M et al. Brain trace elements in Alzheimer's disease. Neurotoxicology7 (1), 195–206 (1986).
   PubMed Web of Science ®Google Scholar
• Adlard PA Bush AI . Metals and Alzheimer's disease. J. Alzheimers Dis.10 (2–3), 145–163 (2006).
   PubMed Web of Science ®Google Scholar
• Lovell MA Robertson JD Teesdale WJ et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci.158 (1), 47–52 (1998).
   PubMed Web of Science ®Google Scholar
• Bush AI . The metallobiology of Alzheimer's disease. Trends Neurosci.26 (4), 207–214 (2003).
   PubMed Web of Science ®Google Scholar
• Bolognin S Messori L Drago D et al. Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1–42) aggregation and toxicity. Int. J. Biochem. Cell Biol.43 (6), 877–885 (2011).
   PubMed Web of Science ®Google Scholar
• Jomova K Vondrakova D Lawson M et al. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell Biochem.345 (1–2), 91–104 (2010).
   PubMed Web of Science ®Google Scholar
• Cherny RA Barnham KJ Lynch T et al. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J. Struct. Biol.130 (2–3), 209–216 (2000).
   PubMed Web of Science ®Google Scholar
• Liu G Garrett MR Men P et al. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta1741 (3), 246–252 (2005).
   PubMed Web of Science ®Google Scholar
• Liu G Men P Kudo W et al. Nanoparticle-chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci. Lett.455 (3), 187–190 (2009).
   PubMed Web of Science ®Google Scholar
• Francis PT Palmer AM Snape M et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatr.66 (2), 137–147 (1999).
   PubMed Web of Science ®Google Scholar
• Standridge JB . Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin. Ther.26 (5), 615–630 (2004).
   PubMed Web of Science ®Google Scholar
• Raschetti R Albanese E Vanacore N et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med.4 (11), e338 (2007).
   PubMed Web of Science ®Google Scholar
• Tse FL Laplanche R . Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharm. Res.15 (10), 1614–1620 (1998).
   PubMed Web of Science ®Google Scholar
• Mutlu NB Degim Z Yilmaz S et al. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev. Ind. Pharm.37 (7), 775–789 (2011).
   PubMed Web of Science ®Google Scholar
• Garberg P Ball M Borg N et al. In vitro models for the blood-brain barrier. Toxicol. In vitro.19 (3), 299–334 (2005).
   PubMed Web of Science ®Google Scholar
• Ismail MF Elmeshad AN Salem NA . Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease. Int. J. Nanomedicine8, 393–406 (2013).
   PubMed Web of Science ®Google Scholar
• Fujimura M Usuki F Kawamura M et al. Inhibition of the Rho/ROCK pathway prevents neuronal degeneration in vitro and in vivo following methylmercury exposure. Toxicol. Appl. Pharmacol.250 (1), 1–9 (2011).
   PubMed Web of Science ®Google Scholar
• Herskowitz JH Seyfried NT Gearing M et al. Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-β production. J. Biol. Chem.286 (8), 6117–6127 (2011).
   PubMed Web of Science ®Google Scholar
• Yang P Wen HZ Zhang JH . Expression of a dominant-negative Rho-kinase promotes neurite outgrowth in a microenvironment mimicking injured central nervous system. Acta Pharmacol. Sin.31 (5), 531–539 (2010).
   PubMed Web of Science ®Google Scholar
• Liu Y Liu Z Wang Y et al. Investigation of the performance of PEG-PEI/ROCK-II-siRNA complexes for Alzheimer's disease in vitro. Brain Res.1490, 43–51 (2013).
   PubMed Web of Science ®Google Scholar
• Craig MC Murphy DG . Alzheimer's disease in women. Best Pract. Res. Clin. Obstet. Gynaecol.23 (1), 53–61 (2009).
   PubMed Web of Science ®Google Scholar
• Sherwin BB . Can estrogen keep you smart? Evidence from clinical studies. J. Psychiatry Neurosci.24 (4), 315–321 (1999).
   PubMed Web of Science ®Google Scholar
• Ohkura T Isse K Akazawa K et al. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia6 (2), 99–107 (1995).
   PubMedGoogle Scholar
• Simpkins JW Singh M . More than a decade of estrogen neuroprotection. Alzheimers Dement.4 (1 Suppl 1), S131–S136 (2008).
   PubMed Web of Science ®Google Scholar
• Vasudevan N Pfaff DW . Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Front Neuroendocrinol.29 (2), 238–257 (2008).
   PubMed Web of Science ®Google Scholar
• Mittal G Carswell H Brett R et al. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. J. Control. Release150 (2), 220–228 (2011).
   PubMed Web of Science ®Google Scholar
• Krol S Macrez R Docagne F et al. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood–brain barrier. Chem. Rev.113 (3), 1877–1903 (2013).
   PubMed Web of Science ®Google Scholar
• Wu X Tan Y Mao H et al. Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int. J. Nanomedicine5, 385–399 (2010).
   PubMed Web of Science ®Google Scholar
• Onoue S Yamada S Chan HK . Nanodrugs: pharmacokinetics and safety. Int. J. Nanomedicine9, 1025–1037 (2014).
   PubMed Web of Science ®Google Scholar
• Frick R Muller-Edenborn B Schlicker A et al. Comparison of manganese oxide nanoparticles and manganese sulfate with regard to oxidative stress, uptake and apoptosis in alveolar epithelial cells. Toxicol. Lett.205 (2), 163–172 (2011).
   PubMed Web of Science ®Google Scholar
• Ginzburg VV Balijepalli S . Modeling the thermodynamics of the interaction of nanoparticles with cell membranes. Nano Lett.7 (12), 3716–3722 (2007).
   PubMed Web of Science ®Google Scholar
• Hutter E Boridy S Labrecque S et al. Microglial response to gold nanoparticles. ACS Nano4 (5), 2595–2606 (2010).
   PubMed Web of Science ®Google Scholar